IMWG consensus recommendations on imaging in monoclonal plasma cell disorders
The IMWG present recommendations on imaging both in clinical practice and in the trial setting to help standardise the best imaging methods to use as myeloma patients progress through different disease stages.
Recent advances in the treatment of multiple myeloma have created a pressing need for accurate disease diagnosis, particularly for detecting bone and bone marrow lesions, which are crucial in guiding treatment decisions. The identification of these lesions often dictates the initiation of treatment, highlighting the importance of timely and precise imaging.
Moreover, the ability to detect minimal residual disease is essential for prognosis determination and treatment planning. This need has underscored the demand for sensitive imaging methods that can effectively assess patient responses to multiple myeloma treatments. For example, low-dose whole-body CT has demonstrated increased sensitivity compared to conventional skeletal surveys in identifying bone disease. This improved detection can lead to adjustments in therapy and disease management, potentially preventing or delaying significant morbidity and mortality associated with skeletal-related events.
Given the array of imaging options available, including conventional skeletal surveys, whole-body CT, PET/CT, and MRI, the International Myeloma Working Group (IMWG) has established guidelines on the optimal use of these imaging methods at various disease stages. These recommendations aim to standardise imaging practices both within and outside of clinical trials, facilitating the comparison of results across different studies and promoting a unified approach to treating multiple myeloma. By ensuring consistency in imaging protocols, the IMWG hopes to enhance patient outcomes and advance the understanding of myeloma management on a global scale.
Use Cases
Type
Source
You might also like
IMWG immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Step into the forefront of myeloma treatment with this latest publication from the International Myeloma Working Group immunotherapy committee.
IMWG GuidelineBSH/UKMS good practice paper on Diagnosis and management of smouldering myeloma
Explore the latest guidelines for Smouldering Myeloma care in the British Society for Haematology Good Practice Paper.
BSH GuidelineNICE guidelines on Spinal metastases and metastatic spinal cord compression [NG234]
This NICE guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC).
NICE GuidelineIMWG recommendations on the management of multiple myeloma-related renal impairment
The IMWG outline updates to clinical practice guidance for the management of multiple myeloma-related renal impairment.
IMWG GuidelineIMWG consensus guidelines and recommendations for infection prevention in myeloma
Infection poses a significant risk to patients with multiple myeloma, contributing to high rates of morbidity and mortality. This consensus statement from the International Myeloma Society outlines essential guidelines for infection prevention
IMWG GuidelineBSH/UKMS guidelines on the Diagnosis, investigation, and initial treatment of myeloma
These new guidelines, produced by the British Society for Haematology (BSH) and the UK Myeloma Society (UKMS), provide healthcare professionals with guidance on the anti-myeloma management of patients with newly diagnosed myeloma.
IMWG recommendations for the treatment of multiple myeloma-related bone disease
This guideline, authored by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the current evidence and offers management recommendations for myeloma-related bone disease.
IMWG GuidelineScottish referral guidelines for suspected cancer
The Scottish Referral Guidelines for Suspected Cancer were created to help GPs, the wider primary care team, other clinicians, patients and carers to identify those people who are most likely to have cancer and who therefore require urgent assessment by a specialist.
Other GuidelineNICE guideline on Acute kidney injury: prevention, detection and management [NG148]
This NICE guideline provides recommendations for non-specialists for the identification and referral guidance for children and adults who present with symptoms or risk factors of acute kidney injury.
NICE GuidelineMY-RADS guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma
As whole-body MRI is listed in NICE guidance as the recommended first line imaging in patients with suspected myeloma, this paper outlines a clinical protocol: the Myeloma Response Assessment and Diagnosis System (MY-RADS), for its use and interpretation.
Other Guideline
